Floatz logo

Atezolizumab

Human Papillomavirus-Related Cervical Squamous Cell Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Human Papillomavirus-Related Cervical Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Veliparib
National Cancer Institute (NCI)
Phase 2B
Rigosertib
Traws Pharma, Inc.
Phase 2B

View all 32 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →